BIOAVAILABILITY OF CEFPODOXIME PROXETIL WITH CO-ADMINISTERED ACETYLCYSTEINE

In a cross-over study on twelve healthy volunteers cefpodoxime proxeti l (CAS 87239-81-4) and acetylcysteine (CAS 616-91-1) were evaluated fo r possible pharmacokinetic interactions. After a standardized breakfas t, the subjects received p.o. either 200 mg cefpodoxime administered a s cefpodoxime proxetil (reference) or 200 mg cefpodoxime and 200 mg ac etylcysteine (test). To determine the pharmacokinetic profile of cefpo doxime the plasma concentrations were determined by HPLC. The plasma c oncentration-time curve of cefpodoxime was very similar after both reg imens, and with respect to cefpodoxime bioequivalence has been proven. The narrow range of 90% confidence intervals for the quotient test/re ference for C-max and AUC indicate reliable bioavailability of cefpodo xime proxetil independent of co-administered acetylcysteine.